Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
42.33
+0.29 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
26
27
Next >
Biogen To Report Q1 Earnings: Here's What To Expect
April 21, 2023
We expect Biogen to beat expectations when it reports first-quarter 2023 results on Apr. 25 before the market opens. In the last reported quarter, the company delivered an earnings surprise of 15.38%.
Via
Talk Markets
FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma
April 20, 2023
Via
Benzinga
FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma
April 19, 2023
From
Genentech
Via
Business Wire
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
April 16, 2023
From
Genentech
Via
Business Wire
Is Roche a Buy Now?
March 20, 2023
Roche focuses on the long-term.
Via
The Motley Fool
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
April 13, 2023
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those...
Via
Benzinga
Trillions In Biotech Stock Gains Trace Back To This Financier
April 13, 2023
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.
Via
Investor's Business Daily
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023
April 13, 2023
From
Genentech
Via
Business Wire
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
April 11, 2023
The company bulks up its pipeline by regaining the rights to two of its clinical programs.
Via
The Motley Fool
Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket
April 10, 2023
Shares are closing in on a buy point out of a consolidation.
Via
Investor's Business Daily
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies
March 30, 2023
Via
Benzinga
Roche's Slow Growth Shouldn't Drive Investors Away
March 28, 2023
New treatments for various cancers, eye diseases, and more may bring in future revenues.
Via
The Motley Fool
Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease
March 22, 2023
Via
Benzinga
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients
March 20, 2023
Via
Benzinga
New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)
March 20, 2023
From
Genentech
Via
Business Wire
Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy
March 17, 2023
Via
Benzinga
Daily Stock Analysis: Roche Holding AG
March 16, 2023
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was...
Via
Talk Markets
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
March 15, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...
Via
FinancialNewsMedia
Exposures
COVID-19
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
March 09, 2023
From
Genentech
Via
Business Wire
FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting
March 09, 2023
Via
Benzinga
The Top 7 Growth Stocks in Biotech
March 03, 2023
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.
Via
InvestorPlace
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
March 03, 2023
Via
Benzinga
Why Sarepta Therapeutics' Shares Rose 23.4% This Week
March 02, 2023
The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval.
Via
The Motley Fool
3 Best Growth Stocks to Buy In March
March 02, 2023
These three red-hot growth stocks have more room to run.
Via
The Motley Fool
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
February 27, 2023
Via
Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
February 23, 2023
Via
Benzinga
Infinity Pharmaceuticals Announce Merger Agreement With MEI Pharma, Share Plunge
February 23, 2023
Via
Benzinga
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
February 21, 2023
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients.
Via
Investor's Business Daily
Biogen Beats Q4 Earnings & Sales Estimates, Stock Up
February 15, 2023
Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05.
Via
Talk Markets
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
February 10, 2023
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.